Repligen (NASDAQ:RGEN) Upgraded at StockNews.com

Repligen (NASDAQ:RGEN) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

A number of other research analysts have also weighed in on RGEN. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. UBS Group lowered their price target on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Benchmark restated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Finally, Stephens reissued an “overweight” rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Stock Performance

Shares of RGEN traded up $0.82 during trading hours on Friday, reaching $142.58. 556,879 shares of the company traded hands, compared to its average volume of 669,440. The business has a fifty day moving average price of $140.20 and a 200-day moving average price of $143.62. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a quick ratio of 5.56, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.99 billion, a P/E ratio of -385.34, a P/E/G ratio of 3.87 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the company earned $0.23 earnings per share. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year. Equities analysts anticipate that Repligen will post 1.52 EPS for the current fiscal year.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Andra AP fonden bought a new position in Repligen in the 2nd quarter valued at about $25,000. International Assets Investment Management LLC bought a new position in Repligen during the 2nd quarter worth approximately $33,000. UMB Bank n.a. raised its position in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the last quarter. Lazard Asset Management LLC boosted its position in Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 136 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.